anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed in the present invention are an ultrasound-assisted scanning method and system. On the basis of generating a real-time ultrasound image, carrying out matching operations on the acquired real-time image and the library image in the image library, so that the correctness of the current scanning operations is immediately fed back to the user. The method can further output image-text help information according to a matching result. If the current real-time image is the standard section image of an tissue or an organ, the relevant image-text information of the standard section is automatically exported, thereby improving the ease of the operations. If failing to obtain the standard section image, prompting the user on how to adjust the position of the probe, thereby quickly and accurately obtaining the desired image. The method and system of the present invention improve the user interaction and user guidance, and can significantly improve the assisted scanning effect.
FIELD: medicine. SUBSTANCE: bactericide has ferric ions (Fe 3+ ) and one or more components of the group consisting of sorbic acid, benzoic acid and p- hydroxybenzoic acid esters. By another variant the bactericide has ferric ions (Fe 3+ ), L-ascorbic acid and one or more components of the group consisting of sorbic acid, benzoic acid or p-hydroxybenzoic acid esters. By the third variant the bactericide has ferric ions, sorbic acid, benzoic acid and L-ascorbic acid. Invention provides to obtain the bactericide exhibiting the high usefulness degree and showing effect with respect to pathogenic bacteria but safe for humans and soil. Invention can be used for sterilization of hands, wounds, fittings, tools, subjects and crude foodstuffs before their heat treatment. EFFECT: enhanced effectiveness of bactericide. 7 cl, 1 dwg, 9 tbl, 8 ex
NEW MATERIAL:A compound expressed by the formula. USE:A vasodilator, ameliorating agent for brain circulation, remedy for stenocardia and preventive and remedial agent for thrombosis and hypertension of cerebrovascular system. PREPARATION:For example, 1-chloroisoquinoline is dripped into a 60% fuming sulfuric acid while cooling with an ice and the resulting solution is heated. Thus obtained solution is discharged into an ice water and stirred. Precipitated crystals are filtered and washed with methanol and ether and dried under reduced pressure to obtain crude crystals of 1-chloro-5-isoquinoline sulfonic acid. Then the crystals are recrystallized from water.
The US National Pain Strategy recommends identifying individuals with chronic pain (CP) who experience substantial restriction in work, social, or self-care activities as having high-impact chronic pain (HICP). High-impact chronic pain has not been examined among individuals with CP and sickle cell disease (SCD). We analyzed data from 63 individuals with SCD and CP who completed at least 5 months of pain diaries in the Pain in Sickle Cell Epidemiology Study (PiSCES). Forty-eight individuals met the definition for HICP, which was operationalized in this study as reporting pain interference on more than half of diary days. Compared with individuals without HICP, individuals with HICP experienced higher mean daily pain intensity, particularly on days without crises. They also experienced a greater proportion of days with pain, days with healthcare utilization, and days with home opioid use and higher levels of stress. They did not have a statistically significantly higher proportion of days with crises or experience higher mean daily pain intensity on days with crises. Individuals with HICP experienced worse physical functioning and worse physical health compared with those without HICP, controlling for mean pain intensity, age, sex, and education. The results of this study support that HICP is a severely affected subgroup of those with CP in SCD and is associated with greater pain burden and worse health outcomes. The findings from this study should be confirmed prospectively in a contemporary cohort of individuals with SCD.
The formation of antibodies to the A-2 plaque virus previously propagated in tissue culture is described. The application describes an immune response against those antibodies and against the A-2 plaque virus antigen which is associated with human viral hepatitis both of type A and B origin. The reaction of antibody for A-2 plaque virus with the antigen from stool specimens of volunteers infected with type A hepatitis and from the sera of patients diagnosed as having type B hepatitis is described. Convalescent sera from both type A and type B hepatitis patients in reaction with the virus, demonstrate the presence of antigenic components in the plaque virus which react with human antibody formed in response to infection with either type A or type B hepatitis. Moreover, the A-2 plaque antibodies react with hepatitis B core antigen, while antibodies to HB c  Ag react with A-2 plaque antigen. Additionally, methods for inducing antibody formation in humans from the A-2 plaque virus antigen are described, as are methods for detecting HB c  Ag, HB c  Ab, HAAg and HAAb.
The first group is treated according to the FAST-FORWARD schedule, consisting of 5 radiation sessions on 5 consecutive working days (e.g. Monday to Friday). 2 rest days are allowed in the schedule, so that the treatment lasts a maximum of 7 days.
Cell plasticity, changes in cell fate, is crucial for tissue regeneration. In the lung, failure of regeneration leads to diseases, including fibrosis. However, the mechanisms governing alveolar cell plasticity during lung repair remain elusive. We previously showed that PCLAF remodels the DREAM complex, shifting the balance from cell quiescence towards cell proliferation. Here, we find that PCLAF expression is specific to proliferating lung progenitor cells, along with the DREAM target genes transactivated by lung injury. Genetic ablation of Pclaf impairs AT1 cell repopulation from AT2 cells, leading to lung fibrosis. Mechanistically, the PCLAF-DREAM complex transactivates CLIC4, triggering TGF-β signaling activation, which promotes AT1 cell generation from AT2 cells. Furthermore, phenelzine that mimics the PCLAF-DREAM transcriptional signature increases AT2 cell plasticity, preventing lung fibrosis in organoids and mice. Our study reveals the unexpected role of the PCLAF-DREAM axis in promoting alveolar cell plasticity, beyond cell proliferation control, proposing a potential therapeutic avenue for lung fibrosis prevention.
The placebo will be administered as a single dose on separate occasions intravenously as 30-minute infusions on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
Ultacan® and Ultacan® forte contain epinephrine, a vasoconstrictor that can cause local or systemic toxicity and should be used cautiously. Local toxicity may include ischemic injury or necrosis, which may be related to vascular spasm. Ultacan® and Ultacan® forte should be used with caution in patients during and following the administration of potent general anesthetic agents, since cardiac arrhythmias may occur under such conditions. Patients with peripheral vascular disease and those with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response.

The American Heart Association has made the following recommendation regarding the use of local anesthetics with vasoconstrictors in patients with ischemic heart disease: “Vasoconstrictor agents should be used in local anesthesia solutions during dental practice only when it is clear that the procedure will be shortened or the analgesia rendered more profound. When a vasoconstrictor is indicated, extreme care should be taken to avoid intravascular injection. The minimum possible amount of vasoconstrictor should be used.” (Kaplan, 1986). 

It is essential to aspirate before any injection to avoid administration of the drug into the blood stream.
BACKGROUND: Children with Hirschsprung disease (HSCR) proximal to the splenic flexure or those needing a redo pull-through (PT) are at risk for tension and ischemia of the PT which could result in leak, stricture, or loss of ganglionated bowel. Colonic derotation is a technique used to minimize tension and avoid duodenal obstruction. The aim of this study was to describe this technique and outcomes in a series of patients requiring this intervention.
METHODS: All patients underwent initial diversion and colonic mapping. The derotation procedure involves mobilization of the remaining colon, counterclockwise rotation via the stoma closure site, placement of the pull through (the right colon) lying on the right of the pelvis, and ligation of the middle colic artery with preservation of the marginal branch running from the ileocolic artery. This maneuver prevents compression of the duodenum by the mesenteric vessels and allows for an isoperistaltic, tension-free anastomosis. Intraoperative indocyanine green fluorescence angiography (ICG-FA) was utilized in many of the cases to map the blood supply of the pull-through colon. We reviewed outcomes for all children with HSCR who underwent colonic derotation from 2014 to 2023. Descriptive statistics were performed.
RESULTS: There were 37 children included. Most were male (67.5%) with the original transition zone proximal to the rectosigmoid (81.1%). The median age at PT was 9.3 months [6.1-39.7]. Median operative time was 6.6 h [4.9-7.4] and 19 cases (51.4%) used ICG-FA. Most children had no 30-day postoperative complications (67.6%); in those who did develop complications, readmissions for electrolyte imbalance was most common (50.0%). There were zero cases of anastomotic leak at PT anastomosis. At long-term follow up, median 4.4 years [2.3-7.0], three children (8.1%) developed an anastomotic stricture, all were amenable to anal dilation, and five experienced episodes of enterocolitis (14.7%). Most children had between 1 and 4 stools per day (58.8%).
CONCLUSION: Colonic derotation is a useful strategy to ensure well-perfused colonic length, protect the marginal artery blood supply, avoid duodenal compression, and ensure a tension-free anastomosis with minimal complications.
TYPE OF STUDY: Original research, retrospective cohort.
LEVEL OF EVIDENCE: III.
Angiogenesis plays a critical role in many pathological processes, including irreversible blindness in eye diseases such as retinopathy of prematurity. Endothelial mitochondria are dynamic organelles that undergo constant fusion and fission and are critical signalling hubs that modulate angiogenesis by coordinating reactive oxygen species (ROS) production and calcium signalling and metabolism. In this study, we investigated the role of mitochondrial dynamics in pathological retinal angiogenesis. We showed that treatment with vascular endothelial growth factor (VEGF; 20 ng/ml) induced mitochondrial fission in HUVECs by promoting the phosphorylation of dynamin-related protein 1 (DRP1). DRP1 knockdown or pretreatment with the DRP1 inhibitor Mdivi-1 (5 μM) blocked VEGF-induced cell migration, proliferation, and tube formation in HUVECs. We demonstrated that VEGF treatment increased mitochondrial ROS production in HUVECs, which was necessary for HIF-1α-dependent glycolysis, as well as proliferation, migration, and tube formation, and the inhibition of mitochondrial fission prevented VEGF-induced mitochondrial ROS production. In an oxygen-induced retinopathy (OIR) mouse model, we found that active DRP1 was highly expressed in endothelial cells in neovascular tufts. The administration of Mdivi-1 (10 mg·kg-1·d-1, i.p.) for three days from postnatal day (P) 13 until P15 significantly alleviated pathological angiogenesis in the retina. Our results suggest that targeting mitochondrial fission may be a therapeutic strategy for proliferative retinopathies and other diseases that are dependent on pathological angiogenesis.
PCT No. PCT/CA95/00434 Sec. 371 Date Jun. 20, 1996 Sec. 102(e) Date Jun. 20, 1996 PCT Filed Jul. 21, 1995 PCT Pub. No. WO96/03506 PCT Pub. Date Feb. 8, 1996An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10 % of that of natural Hin47 protein and preferably substantially the same immunogenic properties as natural Hin47 protein. An isolated an purified nucleic acid molecule encoding the Hin47 analog may be provided in a recombinant plasmid which may be introduced into a cell which is grown to produce the Hin47 analog. Immunogenic compositions comprising the Hin47 analog and the encoding nucleic acid may be formulated as vaccines for in vivo administration to a host, including a human, to confer protection against diseases caused by a bacterial pathogen, including Haemophilus species, such as Haemophilus influenzae, that produces Hin47 protein or a protein capable of inducing antibodies in the host specifically reactive with Hin47 protein. The Hin47 analog and the encoding nucleic acid also may be employed in diagnostic applications.
The disclosure presents a DiNC system and method to contextually communicate and share data amongst networked healthcare entities. It is configured to dynamically design virtual enablement services for the networked healthcare entities. DiNC is a service focused arrangement where communication is core to effect healthcare delivery. It allows user interaction both in context of a case management or in general communication. These interactions can be performed using multiple communication channels. It also facilitates healthcare services between the patients, who visit hospital and present in remote areas, with hospitals and doctors. The services provided are one amongst a catalog including but not limited to appointment scheduling, virtual doctor consultation, care follow ups of the patients and maintaining the case history of individual patients. It can predicts possible treatment outcome and possible epidemic outbreak. Further it provides triaging in healthcare provision by identifying level of care required and a probability of outcome.
Participants assigned to the OMT arm will receive 6 weekly sessions. The provider will perform the following 14 osteopathic procedures 1) lateral (and anteroposterior) translation of vertebrae in the thoracic/lumbar spine; 2) active myofascial stretch to the thoracic spine; 3) occipito-atlanto release; 4) translation of cervical spine; 5) muscle energy techniques of the cervical spine; 6) Spencer technique applied to the shoulder bilaterally; 7) supination/pronation of the forearm; 8) circumduction of the wrist; 9) sacroiliac joint gapping; 10) muscle energy technique applied to adductor muscles of lower extremity; 11) psoas muscle energy technique; 12) hamstring muscle energy technique; 13) articulatory technique applied to the ankle; 14) and muscle energy technique applied to the ankle in dorsi and plantar flexion. Further, each subject will receive cranial assessment and treatment emphasizing the venous sinus techniques and compression of the fourth ventricle (CV-4).
This invention provides a method for inhibiting the growth of a microorganis m that expresses Peptide Deformylase by contacting themicroorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-positive and gra m-negative microorganism, e.g., S. aureus, S . epidermidis, K. pneumoniae, E. aerogenes, E. cloacae, M. Catarrhalis,E. coli , E. faecalis, H. influenzae and P. aeruginosa. This method can be practiced i n vitro, ex vivo and in vivo. Further provided is a method for alleviating the symtoms of an infection by a Peptide_Deformylase expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.
Liver precancerous lesions are the key to improving the efficacy of cancer treatment because of the extremely poor prognosis of HCC patients in moderate and late stages. Obesity-related HCC progression is closely related to the inflammatory microenvironment, in which macrophages are one of the major constituents. In the present study, we ask whether obesity promotes diethylnitrosamine (DEN)-induced precancerous lesions by M1 macrophage polarization. First, an association between obesity and liver precancerous lesions was determined by histopathological observations, immunochemistry and immunoblotting. The characteristics of early precancerous lesions (trabecular thickening) appeared earlier eight weeks in obese mice than in normal diet mice after DEN induction. The glutathione S-transferase placental-1 (Gstp 1) and alpha-fetoprotein (AFP) expression in obese mice after DEN induction was higher than that in the same period after DEN injection in normal diet mice. Furthermore, there was a significant increase in the total macrophage number (F4/80+) of DEN and M1 macrophage number (CD86+F4/80+) in obese mice compared with that in normal diet mice. Besides, the expressions of four pro-inflammatory factors in DEN-induced obese mice were significantly higher compared with that in normal diet mice. Additionally, angiogenesis was revealed by immunostaining assay to be associated with the inflammatory response. All the results demonstrate that obesity promotes DEN-induced precancerous lesions by inducing M1 macrophage polarization and angiogenesis.
The invention relates to a method for inducing the active leaves of a dragon tree to generate dragon blood with fungus. The method comprises the following steps of: 1 preparing solid medium according to a normal method, inoculating Fusarium sp. or Colletetrichum sp., and culturing the fungus according to the normal method; 2 inoculating the cultured fungus onto the leaves of the dragon tree; 3 packaging the fungus culture and the leaves with a plastic cloth so as to extend the survival time of the fungus; 4 stabbing the older leaves with needles in the shape of points so as to enhance an effect for generating grease which is induced by the fungus; 5 after inducing the active leaves of the dragon tree with the fungus for 2-3 weeks, forming the dragon blood; and 6 obtaining grease-containing leaves for generating the dragon blood, drying the leaves, extracting the leaves with ethanol or methanol, and drying the extract to obtain the dragon blood. The invention solves the problems that the fungus of the Fusarium sp. or the Colletetrichum sp. is taken as an inducer for inducing the leaves of the dragon tree to be damaged and the dragon blood to be formed with the feature that the leaves of the dragon tree grow fast and the sustainable use of the dragon tree resources.
The present invention relates to traditional Chinese medicine ointment for treating burns and scalds ('quick effective ointment for treating burns and scalds'), and a preparation method of the traditional Chinese medicine ointment for treating burns and scalds. The traditional Chinese medicine ointment for treating burns and scalds is prepared from 20 grams of lithospermum, 50 grams of phellodendron, 750 grams of Japanese ampelopsis root, 2 milliliters of peppermint oil and 1000 grams of vaseline (auxiliary material) according to a traditional method for decocting ointment. A finished product of the ointment is black; the finished product of the ointment has the functions of removing toxic substances, removing rotten tissues and promoting tissue regeneration, and has the action of eliminating suppuration, healing wounds, sterilizing bacteria, promoting new tissue regeneration. A bandaging treatment method is adopted; firstly, a wound is cleaned by physiological saline, and after the moisture is dried, the ointment of the present invention is coated on the wound; then, the wound is bandaged, and the ointment is changed for one time every day. First degree burns and scalds can be healed within 12 to 24 hours, shallow second degree burns and scalds can be healed within 2 days, deep second degree burns and scalds can be healed within 3 to 5 days, and third degree burns and scalds can be healed within 7 to 15 days; tumors caused by burns and scalds can be eliminated and repaired within certain days. When the ointment of the present invention is properly used, a wound surface can not be infected, healing skin basically can not generate contracture, and no scars remain.
Objective: Alzheimer s disease (AD) is a progressive neurodegenerative disease that impairs memory and other cognitive abilities, as well as behavior and the ability to function independently. It is the most common cause of dementia among older people. Alzheimer s disease is characterized by deficits in several neurotransmitter systems, most prominently acetylcholine (Ach). The cholinergic deficit in the AD brain is associated with the cognitive and functional symptoms in AD. Restoring this deficit in the cholinergic system is one proven approach for symptomatic treatment in AD. The action of Ach in the brain is terminated mainly by two enzymes called cholinesterases (ChEs): acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Inhibitors of these enzymes therefore augment the activity of surviving Ach neurons in AD. All ChEs inhibitors currently approved for the treatment of AD mainly inhibit AChE and, secondarily and to a varying extent, BChE. Reversible and brain-specific BChE inhibitors have been developed as a class of drugs called cymserine analogs. Scientists at the NIA/NIH have developed a novel BChE inhibitor called Bisnorcymserine (BNC). Pre-clinical evidence suggests that BNC may be a safe treatment for Alzheimer s disease. Based on this, we propose this first-in-human study to evaluate the safety, tolerability and pharmacokinetics of single doses of BNC tartrate administered orally.

Study population: Healthy volunteers aged 55 years and older.

Design: Double blind placebo-controlled Phase I clinical Trial of single oral doses of BNC doses in an ascending schedule: 20, 40mg, 80 mg, 120 mg, 160 mg, 270 mg and 380 mg. Each dose will be tested in groups of 8 subjects. Six subjects in each cohort will receive active drug and two will receive placebo. Subjects will be kept in the unit and followed clinically and with laboratory tests for adverse effects for 32 hours; they will return for a follow-up visit to assess safety in about 7 days. A Data Safety Monitoring Board will evaluate the safety and tolerability associated with each dose level before the next higher dose is tested in a new cohort. All research will be performed at the National Institute on Aging (NIA) Clinical Research Unit located on the 5th floor of MedStar Harbor Hospital.
The human immunodeficiency virus (HIV) contains, in addition to the canonical genes gag, pol, and env, an open reading frame in the 3' region of the genome that overlaps with the 3' long terminal repeat (LTR). Initial studies on the protein encoded by this ORF revealed a negative effect on HIV replication in vitro and this gene product was subsequently designated the negative factor, or Nef. The nef gene product is 25-29 kDa protein that localizes primarily to the cytoplasm of HIV-infected cells. The subject of this invention pertains to the discovery of a superantigen activity associated with this peptide and peptidic fragments derived therefrom. Superantigens are powerful T-cell mitogens that bind directly to major histocompatibility complex (MHC) class II molecules and form a binary complex with the variable  beta  (V beta ) region of the T-cell antigen receptor (TCR). It was demonstrated that Nef induces the rapid proliferation of human peripheral mononuclear cells and T-lymphocyte cytokine production. Nef peptidic fragments were also identified that display major histocompatibility complex (MHC) class II binding activity. These peptides can be utilized to generate suitable immune responses in the desired host.